The Alliance for Cancer Gene Therapy has updated the research scope to explicitly include TILs, γδ T cells, CRISPR, and synthetic circuits as supported platforms. If you are preparing an LOI, please note that integrative approaches addressing trafficking, antigen escape, and safety are now strongly encouraged. Deadlines, eligibility, and funding amounts remain unchanged.
Funder: Alliance for Cancer Gene Therapy
Due Dates: May 15, 2026 (Letter of Intent/Abstract) | September 1, 2026 (Full application, invited only)
Funding Amounts: Up to $500,000 total over 2–3 years, including up to 10% indirect costs.
Summary: Supports innovative translational research to overcome barriers in cell and gene therapy for solid tumor cancers.
Key Information: LOI required; research must be conducted at US or Canadian institutions.